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ABSTRACT 
Bleeding is the most serious complication of warfarin anticoagulation therapy and is known to occur even at pa-
tients with therapeutic international normalized ratio (INR) range. Recently, it has been shown that microRNAs 
play a significant role in pharmacogenetics by regulating genes that are critical for drug function. Interaction be-
tween microRNAs and these target genes could be affected by single-nucleotide polymorphisms (SNPs) located 
in microRNA-binding sites. This study focused on 3′-untranslated region (3′-UTR) SNPs of the genes involved in 
the warfarin action and the occurrence of bleeding complications in an Iranian population receiving warfarin. A 
total of 526 patients under warfarin anticoagulation therapy with responding to the therapeutic dose and mainte-
nance of the INR in the range of 2.0-3.5 in three consecutive blood tests were included in the study. Four selected 
3'-UTR SNPs (rs12458, rs7294, rs1868774 and rs34669593 located in GATA4, VKORC1, CALU and GGCX genes, 
respectively) with the potential to disrupt/eliminate or enhance/create microRNA-binding site were genotyped 
using a simple PCR-based restriction fragment length polymorphism (PCR-RFLP) method. Patients with the 
rs12458 AT or TT genotypes of the GATA4 gene had a lower risk of bleeding compared to patients with the AA 
genotype (adjusted OR: 0.478, 95% CI: 0.285-0.802, P= 0.005, OR: 0.416, 95% CI: 0.192-0.902, P= 0.026, re-
spectively). 3'-UTR polymorphisms in other genes were not significantly associated with the risk of bleeding com-
plications. In conclusion, the SNP rs12458A>T in the 3′UTR region of GATA4 is associated with the incidence of 
warfarin-related bleeding at target range of INR, likely by altering microRNA binding and warfarin metabolism. 
Further genetics association studies are needed to validate these findings before they can be implemented in clinical 
settings. 
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INTRODUCTION  
Warfarin was introduced into clinical 
practice in the 1950s and since has become 
the mainstay of oral anticoagulant treatment 
in the world (Jones and Miller, 2011). Over 
60 years, warfarin has been in clinical use for 
treatment and/or prevention of pulmonary 
embolism, venous thrombosis, and other 
thromboembolic events associated with myo-
cardial infarction, atrial fibrillation and the 
conditions requiring coagulation control 
(Wysowski et al., 2007; Kimmel, 2008). De-
spite approval of several new oral anticoagu-
lant medications, warfarin is still prescribing 
as a beneficial anticoagulant in prosthetic 
heart valve (Anderson and Marrs, 2018; 
Durães et al., 2018) and in low socioeconomic 
populations (Desai et al., 2014). 
Considering the warfarin narrow thera-
peutic window, regular monitoring and main-
taining a patient’s international normalized 
ratio (INR) within a therapeutic range is de-
manded for achieving desired anticoagulation 
(Lee and Klein, 2013; Emery, 2017). INR is 
an international standardized number for the 
prothrombin time (PT). For most indications, 
the most widely accepted therapeutic INR 
range for warfarin treatment is 2.0 to 3.0 
(Wadelius et al., 2009; Lee and Klein, 2013). 
However, in patients with valvular heart dis-
ease and those with prosthetic heart valves 
INR value increases to 3.5 (Goldsmith et al., 
2002). 
Bleeding is the major adverse effect of 
oral anticoagulant therapy following the treat-
ment and prevention of thromboembolic com-
plications in usual care settings (Palareti et al., 
1996; Epstein et al., 2010). Patients on warfa-
rin are also at increased bleeding tendency 
(Campbell and Gallus, 2001; Wu, 2018). 
Warfarin-induced bleeding commonly occurs 
during the first 90 days of treatment, leads to 
increased morbidity, mortality, and higher 
cost of health care (Lund et al., 2012; Nek-
kanti et al., 2012). Typically, the incidence of 
bleeding is associated with the over-anticoag-
ulation and increases parallel to an elevation 
of INR and fifty percent of bleeding events is 
observed when the INR value is less than 4.0 
(Campbell and Gallus, 2001; Lee and Klein, 
2013). 
Although having INR within accepted 
therapeutic ranges reflects the optimal clinical 
outcomes of warfarin therapy, even when pa-
tients are within the therapeutic INR range 
can suffer serious bleeding complications 
(Pourgholi et al., 2016). Several patient-re-
lated clinical factors including age, gender, 
concomitant drug intake, duration of warfarin 
use, concurrent diseases, history of bleeding 
complication, and warfarin indication have 
been considered to be risk factors for warfa-
rin-related bleeding complications and also 
contribute to inter-individual variability in 
warfarin response (Jones and Miller, 2011; 
Nekkanti et al., 2012). Besides these patient 
and clinical factors, a major portion of the 
variation in warfarin response remains in part 
unexplained (Tang et al., 2017).  
Accumulating evidence supports that ge-
netics is a predictive factor of the final drug 
response and pharmacogenetics-based thera-
pies with warfarin have been associated with 
a reduced risk of excessive anticoagulation 
and hemorrhage complications (Aithal et al., 
1999; Sridharan et al., 2016).  
Products of two important genes, 
VKORC1 (vitamin K epoxide reductase com-
plex subunit 1) and CYP2C9, are responsible 
for the majority of the pharmacodynamics and 
pharmacokinetics of warfarin, respectively 
(Farzamikia et al., 2018; Wu, 2018). Firstly, 
warfarin is metabolized by the hepatic 
CYP2C9 enzyme and then inhibits the coagu-
lation cascade through the targeting of the 
VKORC1 enzyme to decrease the active vita-
min K regeneration from vitamin K epoxide 
(Krajciova et al., 2014; Sridharan et al., 
2016).   
There is overwhelming evidence that sin-
gle nucleotide polymorphisms (SNPs) in the 
CYP2C9 and VKORC1 genes are strongly as-
sociated with variability in dose requirements 
and occurrence of bleeding complications 
during warfarin treatment (Jones and Miller, 
2011; Relling and Evans, 2015). Various 
studies showed that VKORC1 (−1639G>A) 
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rs9923231 polymorphism may cause or be as-
sociated with up to forty percent of the dose 
variation in some populations and, in compar-
ison with the wild type, individuals carrying 
this polymorphism showed lower warfarin re-
quirements (Krajciova et al., 2014; Bader and 
Elewa, 2016).  
Numerous other genes including the mi-
crosomal epoxide hydroxylase (EPHX1), γ-
glutamyl carboxylase (GGCX), calumenin 
(CALU) and GATA binding protein 4 
(GATA4), also have been implicated to deter-
mine the inter-individual variability in warfa-
rin response (Mwinyi et al., 2009; Shahabi et 
al., 2018). To our knowledge, few studies 
have directly investigated the effect of 3′-un-
translated region (3′UTR) SNPs of warfarin-
related genes on clinical outcomes such as the 
incidence of bleeding events due to warfarin 
therapy. In this study, we selected 4 SNPs 
with the potential to disrupt/eliminate or en-
hance/create miRNA-binding sites in the 
3′UTR of some genes involved in warfarin ac-
tion. The aim of this study was to explore the 
association between these variants and bleed-
ing complications in Iranian patients receiv-
ing warfarin with an INR within the 
therapeutic range.  
 
METHODS 
Study design and study population 
The present study, which was planned as 
cross-sectional, was conducted between Jan-
uary and September 2018, at Tehran Heart 
Center (THC). A total number of 526 patients 
with the following inclusion criteria were in-
cluded the study comprising patients who 
used warfarin following atrial fibrillation, val-
vular disease, deep vein thrombosis (DVT), 
pulmonary thromboembolism (PTE) and the 
use of warfarin and response to the therapeu-
tic dose with INR maintenance in the range of 
2.0-3.5 in three consecutive blood tests. Pa-
tients were enrolled in the study when written 
informed consent was obtained from eligible 
patients. The patients with serious complica-
tions, including malignancies, acute infec-
tions, alcohol intake, using glucocorticoids 
and herbal drugs, pregnancy, and other con-
current treatment interacting with warfarin 
were excluded from this research. The study 
design was confirmed by the local Ethics and 
Human Rights Committee and carried out ac-
cording to the guidelines of the Helsinki Dec-
laration. 
 
Collection of clinical data 
Data regarding the gender, age, warfarin 
therapy duration, body weight, valve prosthe-
sis, height, daily warfarin dose, concurrent 
medication, indication for therapy, INR meas-
urements, comorbidity, and history of bleed-
ing complication were gathered from the 
medical records of patients. Other data in-
cluding blood pressure, diet, medication his-
tories, alcohol, and changes in warfarin dose 
were recorded at each physician visit. Then, 
we obtained variables concerning patient's 
characteristics such as laboratory information 
and cardiovascular risk factors by using hos-
pital database. The incidence of different 
types of bleedings, including epistaxis, hema-
turia, gingival, gastrointestinal, vaginal, and 
subconjunctival was recorded throughout the 
entire period of observation and defined as 
those needing medical intervention to treat or 
stop bleeding. In the present study, warfarin 
therapy duration was defined as the number of 
days between beginning of warfarin admin-
istration and the last clinical visit. 
 
Laboratory analysis 
Two blood samples were taken from each 
patient for INR measurement, and DNA ex-
traction. About 5 ml of whole blood was col-
lected in tubes containing ethylenediamine 
tetraacetic acid (EDTA) and frozen for DNA 
extraction and future use. For INR calcula-
tion, plasma was separated from the blood 
sample by centrifugation at 1500 rpm for 15 
min and then the PT with INR were measured 
with a coagulation analyzer–the ACL-
ELITE-PRO (Instrumentation Laboratory, 
USA). 
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Single nucleotide polymorphism selection 
Several specialized miRNA-target SNP 
databases (miRNASNP2, miRSNP, 
miRdSNP, MicroSNiPer) were used to iden-
tify SNPs with the potential to disrupt/elimi-
nate or enhance/create miRNA-binding sites 
within the 3′UTR of genes involved in the ac-
tion of warfarin. Among the suggested SNPs, 
those with MAF (minor allele frequency) 
higher than 0.1 were chosen. Moreover, min-
imum free energy of hybridization (MFE) for 
the selected 3′UTR SNPs were calculated us-
ing RNAcofold Web Server for the wild and 
the variant alleles (Gruber et al., 2008). Fi-
nally, four polymorphisms in the 3′UTR of 
four genes involved in the warfarin action 
were selected. These SNPs included: 
rs1868774G>A, rs34669893G>A, 
rs12458A>T, rs7294G>A in the 3′UTR re-
gions of CALU, GGCX, GATA4, and 
VKORC1 genes respectively. In silico pre-
dicted miRNAs relating to these SNPs also 
are listed in Table 1.  
 
DNA extraction and genotype analysis 
Leukocyte genomic DNA of each patient 
was extracted from peripheral blood samples 
containing EDTA according to the ‘salting 
out’ method. DNA was quantified by measur-
ing the optical density (OD) at λ = 260 nm. 
The 260/280 ratio was used to assess the qual-
ity of DNA being close to 1.8. The SNP gen-
otypes of VKORC1 (rs7294), CALU 
(rs1868774), GGCX (rs34669893) and 
GATA4 (rs12458) variants, were determined 
by restriction enzyme digestion following 
polymerase chain reaction amplification of 
genomic DNA using designed primers and 
corresponding restriction enzymes listed in 
Table 2. The restriction enzyme (1 U) was 
added to PCR products and digestion was per-
formed. After incubation for overnight (16 h) 
at 55 °C, 37 °C and 60 °C for SmlI, AluI and 
MwoI enzymes, respectively, the digested 
fragments and products of PCR were ana-
lyzed on ethidium bromide-stained agarose 
gel and visualized under ultraviolet light. Fi-
nally, the genotypes of each sample were de-
termined from the digestion patterns of bands 
in the gel electrophoresis.  
 
Statistical analysis 
In this study variables were evaluated for 
normal distribution by using the Kolmogo-
rov–Smirnov normality test. The independent 
two-sample Student t-test (or Mann-Whitney 
U test if required) and the chi-square test were 
used to compare the difference between two 
groups of patients with bleeding complica-
tions (bleeding group) and without bleeding 
complications (non-bleeding group) for cont- 
 
 
Table 1: Selected SNPs and their relevant genes and miRNAs 
SNP/Gene SNP position 
(3’UTR) 
miRNAs 
rs7294/VKORC1 +134G>A miR-4466, miR-4322, miR-4265, miR-4296, miR-
147b, miR-147a 
rs12458/GATA4 +1256A>T miR-362-5p, miR-526b, miR-502-5p, miR-500b, 
miR-4279, miR-556-5p 
rs1868774/CALU +3761G>A miR-4526, miR-628-5p, miR-3194-3p, miR-93-3p, 
miR-4686, miR-345-5p, miR-3664-5p, miR-380-5p, 
miR-1267, miR-366 
rs34669893/GGCX +3047G>A miR-221-3p, miR-222-3p 
3’UTR= 3’untranslated region; SNP= single nucleotide polymorphism 
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Table 2: Primer sequences and RFLP fragments of suggested genes 
Gene SNP Sequence of forward (F) and  
reverse (R) primers 
Re-
striction 
enzyme  
RFLP frag-
ments (bp) 
VKORC1 rs7294 F: 5-GCAAGGCTAAGAGGCACTGAG-3 
R: 5-CACACACTGGAGATGAGACTACC-3 
Mwol     448, 295,153 
GATA4 rs12458 F: 5-TCCTCCTAGCCCTTGGTCAGATG-3 
R: 5-GTGGGTTAGGGAGGGTATACGAGG-3 
SmlI 464,268,196 
CALU rs1868774 F: 5-GGAGATAACCTTGGCAGATGAGG-3 
R: 5-CCTACTTTCAGATGGTATTGTTTCCTC-3 
Mwol     380,246,134 
GGCX rs34669893 F: 5-GATGCCAATACATTGCAGATAAC-
CATATTAG-3 
R: 5-CTTAGCAAATACTGAACATAACCTTAAA-
GCG-3 
AluI 135,104,31 
CALU= calumenin; GGCX= γ-glutamyl carboxylase; GATA4= GATA binding protein 4; RFLP= restriction 
fragment length polymorphism; VKORC1= vitamin K epoxide reductase complex subunit 1 
 
 
 
inuous variables and categorical variables, re-
spectively. In both groups, Hardy Weinberg 
equilibrium for all polymorphisms was ana-
lyzed by Chi-square test. Association between 
the genotypes and bleeding following warfa-
rin therapy was recomputed using multivari-
ate logistic regression after adjustment for co-
variates. Odds ratio and 95% confidence in-
terval (CI) were determined to measure the 
association between variables. A p-value 
≤0.05 was declared statistically significant. 
All statistical calculations were performed by 
PASW Statistics for Windows, Version 18.0 
(SPSS Inc., Chicago, USA). 
 
RESULTS 
Of a total of 526 patients meeting the eli-
gibility criteria, 82 (15.6 %) patients had 
bleeding complications with a mean INR of 
2.7 ± 0.4 that was in the therapeutic range. 
Eighty-three bleeding events (minimal hem-
orrhage) were observed and one patient had 2 
bleeding episode (epistaxis and gingival). 
Major life-threatening bleeding complica-
tions were not observed among patients. The 
most frequent site of bleeding was epistaxis 
53 % (44/83). The other sites of bleeding ar-
ranged in descending order of frequency in-
cluded; Hematuria and gingival (each was 
11 %), gastrointestinal (10 %), vaginal (4 %) 
and subconjunctival hemorrhage (3 %). Pa-
tients had a mean age of 58 ± 12 years (be-
tween the ages of 16 and 88 years), 47 % were 
male and 53 % female. Mean stable warfarin 
dose was 36 ± 17 milligram per week and the 
mean length of warfarin therapy was 
1446 ± 790 (133-4432) days. Indications for 
warfarin therapy were included prosthetic 
valve (63 %), atrial fibrillation (21 %), throm-
boembolic disease (12 %) and other indica-
tions (4 %). 
Demographic characteristics of study par-
ticipants are demonstrated in Table 3. Data 
showed significant differences in the age, 
INR, antibiotics and CYP inducers between 
bleeding and non-bleeding groups. There was 
no significant difference in gender, comorbid-
ities, average warfarin dose, and body mass 
index between bleeding and non-bleeding 
groups. 
The distribution of all four SNPs was 
found to be in Hardy Weinberg Equilibrium 
(HWE χ2<3.84 and p>0.05). Table 4 provides 
the genotype frequencies for the analyzed pol-
ymorphisms and the logistic regression model 
before and after adjustment that GATA4 and 
GGCX adjusted for age and CYP inducers, 
VKORC1 and CALU adjusted for age. Results 
showed that patients with heterozygous (AT) 
and homozygous mutant (TT) genotypes of 
GATA4 rs12458, had a lower risk of bleeding 
than patients with the homozygous wild (AA) 
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genotype (adjusted OR: 0.478, 95% CI: 
0.285-0.802, P= 0.005, OR: 0.416, 95% CI: 
0.192-0.902, P= 0.026 respectively). There 
were no significant associations between 
other selected variants in VKORC1, CALU, 
and GGCX genes and the risk of bleeding 
events. 
 
DISCUSSION  
The current study found that GATA4 
rs12458 genotype is significantly associated 
with bleeding complications at normal INR in 
Iranian patients during warfarin treatment. As 
far as we know, this is the first attempt to em-
pirically examine the relevance of genetic 
variations of GATA4 and CALU and GGCX in 
bleeding complications despite of normal 
INR. 
 
Table 3: Demographic, clinical and laboratory characteristics of the study groups 
Characteristics non-bleeding 
(n=444) 
bleeding 
(n=82) 
P-value 
Age (years) 58.46 ± 12.58 61.10 ± 12.23 0.155* 
Gender (Male) 210 (47.3) 37 (45.1) 0.717 
Body mass index (kg/m2) 26.81 ± 4.3 27.43 ± 4.2 0.242 
Body surface area (m2) 1.80 ± 0.18 1.81 ± 0.16 0.533 
INR 2.71 ± 0.42 2.90 ± 0.40 <0.001* 
Average warfarin dose (mg/week) 36.11 ± 17.75 35.76 ± 17.98 0.879 
Time on warfarin (days) 1438 ± 18 1492 ± 17 0.311 
Warfarin indication    
    Atrial fibrillation 98 (22.1) 13 (15.9) 0.398 
    PTE, DVT, LV clot 50 (11.3) 13 (15.9)  
    Prosthetic valve 279 (62.8) 54 (65.9)  
    Other 17 (3.8) 2 (2.4)  
Comorbidity    
   Thyroid disease 47 (10.6) 5 (6.1) 0.211 
   Chronic kidney disease 6 (1.4) 2 (2.4) 0.461 
   Liver disease 6 (1.4) 0 (0) 0.290 
   Congestive heart failure 56 (12. 6) 13 (15.9) 0.790 
   Diabetes 76 (17.1) 15 (18.3) 0.796 
   Hypertension 202 (45.5) 42 (51.2) 0.340 
   Hyperlipidemia 187 (42.1) 37 (45.1) 0.613 
Smoking 25 (5.6) 7 (8.5) 0.314 
Medications    
    CYP inducers 
    (Rifampin, Carbamazepine, Phenytoin) 
9 (2) 6 (7.3) 0.008* 
    Amiodarone 11 (2.5) 2 (2.4) 0.984 
    Antibiotics 3 (0.7) 3 (3.7) 0.019* 
    Antiplatelet drugs 232 (52.3) 44 (53.7) 0.815 
    NSAIDs 13 (2.9) 3 (3.7) 0.723 
    Digoxin 100 (22.5) 19 (23.2) 0.897 
    Aloporinol 7 (1.6) 1 (1.2) 0.808 
Fasting blood sugar (mg/dl) 109.03 ± 3.47 109.00 ± 1.66 0.502 
Triglyceride (mg/dl) 142.10 ± 3.40 141.67 ± 3.77 0.714 
HDL-cholesterol (mg/dl) 41.24 ± 0.54 42.35 ± 1.11 0.374 
LDL- cholesterol (mg/dl) 108.75 ± 4.5 109.49 ± 1.70 0.449 
Total cholesterol (mg/dl) 173.34 ± 3.73 175.73 ± 2.55 0.915 
Data are presented as mean ± standard deviation or n (%) unless otherwise stated.  
CYP= cytochrome P450; DVT= deep vein thrombosis; LV= left ventricular; NSAIDs= nonsteroidal anti-
inflammatory drugs; PTE= pulmonary thromboembolism. 
* Significance value (P<0.20)  
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Table 4: Genotype frequencies of examined polymorphisms and logistic regression analysis showing odds ratios for bleeding complications 
Variables non-bleeding  
(n=444) 
bleeding  
(n=82) 
Crude OR (95% CI) Adjusted OR (95% CI)a 
OR 95% CI P-value OR 95% CI P-value 
VKORC1 rs7294 GG 
                              GA 
                             AA 
175 (39.4) 
209 (47.1) 
60 (13.5) 
41 (50) 
33 (40.2) 
8 (9.8) 
1 (Ref) 
0.674 
0.569 
- 
(0.409-1.112) 
(0.253-1.282) 
- 
0.122 
0.174 
1 (Ref) 
0.676 
0.573 
- 
(0.409-1.116) 
(0.254-1.292) 
- 
0.126 
0.179 
GATA4  rs12458            AA 
                                         AT 
                                         TT 
149 (33.6) 
214 (48.2) 
81 (18.2) 
44 (53.7) 
29 (35.4) 
9 (11) 
1 (Ref) 
0.459 
0.376 
- 
(0.275-0.767) 
(0.175-0.810) 
- 
0.003* 
0.012* 
1 (Ref) 
0.478 
0.416 
- 
(0.285-0.802) 
(0.192-0.902) 
- 
0.005* 
0.026* 
CALU  rs1868774           GG 
                                        GA 
                                        AA 
181 (40.8) 
201 (45.3) 
62 (14) 
32 (39) 
33 (40.2) 
17 (20.7) 
1 (Ref) 
0.929 
1.551 
- 
(0.549-1.572) 
(0.806-2.986) 
- 
0.783 
0.189 
1 (Ref) 
0.942 
1.565 
- 
(0.556-1.596) 
(0.811-3.022) 
- 
0.824 
0.182 
GGCX  rs34669893        GG 
                                        GA 
                                        AA 
297 (66.9) 
124 (27.9) 
23 (5.2) 
55 (67.1) 
25 (30.5) 
2 (2.4) 
1 (Ref) 
1.089 
0.470 
- 
(0.649-1.826) 
?0.108-2.049) 
- 
0.747 
0.315 
1 (Ref) 
1.177 
0.532 
- 
(0.696-1.990) 
(0.121-2.333) 
- 
0.544 
0.402 
Frequency data are presented as n(%). 
aLogistic regression model adjusted for age and CYP inducers (for VKORC1 and CALU only age and for GATA4 and GGCX, age and CYP inducers).  
OR= odds ratio; CI= confidential interval; Ref= the reference category. 
*Significance value (P<0.05) 
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GATA4, a member of transcription factor 
family GATA containing two zinc finger 
DNA binding domains, consists of 442-amino 
acids and binds to a (A/T)GATA(A/G) se-
quence (Reamon-Buettner et al., 2007). 
GATA4 is expressed in several endoderm- and 
mesoderm-derived tissues such as liver, small 
intestine, heart, lungs, and gonads as a critical 
tissue-or cell type-specific gene regulator 
(Molkentin, 2000). When expressed in the 
embryonic heart and yolk sac endoderm, 
GATA4 is involved in cardiac development 
and cardiomyocyte differentiation in the 
embryonic and postnatal heart (Pulignani et 
al., 2016). GATA4 also has been shown to 
specifically regulate expression of the inter-
leukin-5 gene in a human T-cell line 
(Molkentin 2000). In humans, GATA4 gene 
mutations are highly associated with congen-
ital heart defects (Reamon-Buettner et al., 
2007).  
Moreover, it has previously been shown 
that GATA4, as a liver-specific transcription 
factor, regulates the expression of different 
liver detoxifying enzymes and transporters 
(Mwinyi et al., 2009; Jeong et al., 2015). To 
date, several studies have shown that GATA4 
is strongly involved in the transcriptional ac-
tivation of human CYP2C9, a principal me-
tabolizing enzyme in the warfarin pharmaco-
logical pathway (Mwinyi et al., 2009; Van 
Schie et al., 2012). There are some essential 
regulatory elements such as several GATA4-
binding motifs in the proximal promoter re-
gion of the CYP2C9 gene enabling GATA4 to 
affect the expression of the CYP2C9 enzyme 
(Jeong et al., 2015).   
Mwinyi et al. (2009) reported upregula-
tion of promoter activity in wild-type 
CYP2C9 by liver-specific transcription factor 
GATA4. They investigated four putative 
GATA binding sites within CYP2C9 pro-
moter sequence using luciferase gene reporter 
and electrophoretic mobility shift assays. In-
terestingly, mutations located in GATA4-
binding sites dramatically decreased this in-
duction (Mwinyi et al., 2009). A recent inves-
tigation described that polymorphisms in nu-
clear receptor genes are potentially associated 
with alteration in CYP2C9 expression and al-
tered drug metabolism (Shahabi et al., 2018). 
Genetics variations in GATA4 have been pos-
tulated to play a significant role in the inter-
individual variability in drug response (Van 
Schie et al., 2012). Results of a research car-
ried out on a population of Korean patients 
with prosthetic cardiac valve showed an asso-
ciation between GATA4 variants rs2645400 
and rs4841588 and warfarin dose require-
ments through the CYP2C9 expression regu-
lation (Jeong et al., 2015). Another study con-
ducted on a population of Netherlands pa-
tients revealed that one variant in GATA4 in-
fluenced the dose requirement of a warfarin 
derivative, acenocoumarol, in the patients 
having a specific CYP2C9 genotype (Van 
Schie et al., 2012).   
The relationship between warfarin-in-
duced bleeding and CYP2C9 genotypes has 
been widely investigated (Sanderson et al., 
2005; Samardžija et al., 2008; Ucar et al., 
2013; Yang et al., 2013; Pourgholi et al., 
2016). To examine this issue, one group car-
ried out an experiment on 185 patients who 
were under anticoagulation therapy with war-
farin to find if CYP2C9 gene variants can af-
fect the occurrence of bleeding complications. 
They observed a significantly higher rate of 
bleeding complications in CYP2C9*2 and *3 
carriers compared to non-carriers (Marga-
glione et al., 2000). Results of a cohort study 
on two hundred patients showed that 
CYP2C9*2 and *3 polymorphisms are associ-
ated with over-anticoagulation and incidence 
of bleeding during warfarin therapy (Higashi 
et al., 2002). Kawai et al. identified that pa-
tients with a CYP2C9*3 polymorphism had a 
significantly increased risk of bleeding after 
receiving warfarin (Kawai et al., 2014). 
Moreover, results of a meta-analysis and sys-
tematic review from 22 reports indicated that 
CYP2C9*2 and CYP2C9*3 genotypes are ge-
netic risk factors for warfarin hemorrhagic 
complications (Yang et al., 2013). In contrast, 
findings of a study conducted on Korean pop-
ulation with mechanical cardiac valves 
showed that CYP2C9 rs1057910 and 
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VKORC1 rs9934438 variants were not signif-
icantly associated with increased risk of 
bleeding due to warfarin therapy at therapeu-
tic INR (An et al., 2014). In a recent study, 
Sridharan et al. confirmed findings of previ-
ous studies regarding the significant associa-
tion between CYP2C9 genotypes and in-
creased risk of bleeding events following war-
farin therapy (Sridharan et al., 2016). In a 
cross-sectional study on 552 warfarin-treated 
patients with target INR level of 2.0–3.5, 
Pourgholi et al. demonstrated that SNP 
C609T within quinoneoxidoreductase 1 
(NQO1) and haplotypes of CYP2C9 (1*2 or 
1*3) significantly associated with bleeding 
complications (Pourgholi et al., 2016). In 
view of all that has been mentioned so far, one 
may suppose that significant association be-
tween GATA4 SNP and bleeding events, ob-
served in the present study, may be due to the 
transcriptional effect of GATA4 on CYP2C9 
gene. 
Previous investigations have demon-
strated that variants of VKORC1 are associ-
ated with bleeding risk upon warfarin therapy 
(Schwarz et al., 2008). VKORC1 (1639G>A) 
functional promoter SNP showed an in-
creased incidence in occurrence of bleeding 
complications during warfarin therapy in AA 
genotype group (Lund et al., 2012). In a study, 
Mazur-Bialy et al. reported that CYP2C9*3/ 
VKORC1*2A haplotype in a Polish patient 
had a higher sensitivity and bleeding event in 
warfarin-treated patients (Mazur-Bialy et al., 
2013). Sridharan et al. have also shown that 
VKORC1 (1639G>A) mutant allele is associ-
ated with increased bleeding tendency due to 
warfarin therapy (Sridharan et al., 2016). 
Biswas et al. have a recent publication re-
sulted from a study on a population of Indian 
patients in which they showed that AG/AA 
haplotype of VKORC1 (1639G>A) 
rs9923231 was associated with increased risk 
of warfarin bleeding episodes (Biswas et al., 
2018). In contrast to these findings, in our in-
vestigation, no evidence of an association be-
tween selected SNP in 3'-UTR of VKORC1 
and occurrence of bleeding was detected. 
Moreover, in the present study, no association 
was observed between selected SNPs in 
CALU and GGCX genes and bleeding epi-
sodes. 
MicroRNAs, an abundant group of single-
stranded noncoding RNAs comprised of 18-
24 nucleotides, binding to the 3'-UTR se-
quences of target mRNAs and leading to deg-
radation or translation inhibition of their tar-
get genes, play significant regulatory roles in 
the post-transcriptional level (Ciccacci et al., 
2015; Rad et al., 2018). Several reports have 
shown that SNPs within microRNA binding 
sites could affect the expression of target 
genes and influence on drug responses or risk 
of a disease (Swart and Dandara, 2014; 
Pulignani et al., 2016). Shomron et al. identi-
fied two binding sites for miR-133 and miR-
137 on VKORC1 mRNA and suggested regu-
lation of VKORC1 expression by these miR-
NAs (Shomron, 2010). This result is in accord 
with the finding of a recent investigation indi-
cating that miR-133a interacted with the 
3′UTR of VKORC1. It is noticeable that focus 
of this study was on the SNPs of mir-133 
gene, MIR133A2 and MIR133B, which en-
code miR-133a-2 and miR-133b, respec-
tively, to examine the association between 
miR-133 SNPs and stable warfarin dose in 
Han Chinese patients with mechanical heart 
valve replacement (Tang et al., 2017). Results 
of an experiment carried out by in vivo, in 
vitro, and in silico analyses, demonstrated that 
suppression of CYP2C9 expression correlated 
with the expression of miR-128 in hepatocel-
lular carcinoma tumor tissues (Yu et al., 
2015).  
In our study, we identified six miRNAs 
which their binding site disrupt/enhance on 
the GATA4 mRNA following rs12458A>T 
SNP. These miRNAs included; miR-556-5p, 
miR-4279, miR-500b, miR-502-5p, miR-
526b, and miR-362-5p. So far, the association 
between these miRNAs, probably target the 
3′UTR of GATA4, with bleeding complica-
tions after warfarin therapy have not been re-
ported in the literature. Two independent 
studies reported that SNPs in the 3'-UTR of 
GATA4 gene may play a role in the pathogen-
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esis of congenital heart disease (CHD) proba-
bly by modifying miRNA post-transcriptional 
gene regulation (Reamon-Buettner et al., 
2007; Pulignani et al., 2016). Another study 
also points out that common variants in the 
3′UTR of GATA4 are involved in congenital 
heart defects (Sabina et al., 2013). Han et al. 
investigated the GATA4-regulating transcrip-
tional vs. post-transcriptional mechanisms in 
the heart and reported an increased GATA4 
protein level during cardiac hypertrophy re-
sulted possibly from miR-26b post-transcrip-
tional regulation (Han et al., 2012). It has 
been shown that a transcription factor named 
pregnane X receptor (PXR), involved in ex-
pression regulation of drug-metabolizing en-
zymes comprising cytochrome P450 3A4 
(CYP3A4), post-transcriptionally is regulated 
by miR-148a influencing the levels of 
CYP3A4 in human liver (Takagi et al., 2008). 
Interestingly, in a study Takagi et al. found 
that one another transcription factor, HNF4A 
(hepatocyte nuclear factor 4 alpha) which reg-
ulates expression of transporters and endo/xe-
nobiotic-metabolizing enzymes, was down-
regulated by miR-24 and miR-34a thus de-
creased cytochrome P450 7A1 and 8B1 genes 
in HepG2 cells (Takagi et al., 2010). Accord-
ing to these study reports, our results can be 
explained by considering that six identified 
miRNAs could possibly modify the activity of 
the transcription factor GATA4 following 
rs12458 polymorphism and, as mentioned 
above, the GATA4 is a modulator of CYP2C9 
expression, therefore, it is considerable that, 
compared with the wild-type allele, heterozy-
gous and homozygous mutant allele of 
rs12458A>T could disrupt or enhance 
miRNA-binding sites within the 3′UTR of 
GATA4 gene resulting in altered warfarin me-
tabolism that may lead to bleeding complica-
tions. 
A key strength of the present study is that 
we performed this study on a group of Iranian 
patients under warfarin therapy aiming for an 
optimal INR level of 2.0 to 3.5 who continued 
the INR range during three consecutive blood 
tests. This was of a great advantage to inves-
tigate possible consequences of specific ge-
netic variants related to warfarin on the risk of 
bleeding complications at therapeutic range 
of INR after adjustment for multiple demo-
graphic and clinical factors. Moreover, this 
study suffer from some limitations require to 
be considered. This research is limited by its 
cross-sectional design. Moreover, the limited 
number of patients with bleeding led to 
insufficient statistical power. Another limita-
tion is that we do not examine all of the 
polymorphisms with the highest amount of to-
tal free energy. However, we might lose some 
of the critical variants and their relevant miR-
NAs. On the other hand, the functional effect 
of bleeding-associated SNP on target interac-
tion of six suggested miRNAs was not inves-
tigated. Finally, this study was conducted in a 
single center and therefore findings cannot be 
extended to other ethnic groups and further 
studies need to be carried out on populations 
of different genetic backgrounds. 
 
CONCLUSION 
The results of this investigation show that 
SNP rs12458 within a specific region of 
GATA4 3′UTR is associated with bleeding 
complications of warfarin at therapeutic range 
of INR, likely by altering the transcriptional 
gene regulation CYP2C9. Further genetics as-
sociation studies are needed to examine the 
effects of different variants in the 3′UTR re-
gion of GATA4 gene on the occurrence of 
bleeding events in patients under anticoagu-
lant therapy and interpret and generalize these 
results before they can be implemented in the 
context of real clinical practice. Moreover, 
more functional studies on the influence of 
different SNPs in miRNA binding sites will 
be a base line to better give further insights 
into the mechanisms of action of drug or 
chemical responses and individualized ther-
apy in advanced. 
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